The Company expects adjusted EBITDA for 2024 to be $25 to $30 million, up over 75% at the midpoint, representing an adjusted EBITDA margin of at least 15%, up over 600 basis points compared to 2023.
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/1/2024 | $37.00 → $25.00 | Outperform | Barrington Research |
| 8/14/2023 | $24.00 | Mkt Perform → Outperform | Barrington Research |
| 3/7/2023 | Outperform → Mkt Perform | Barrington Research | |
| 11/9/2022 | $31.00 | Mkt Perform → Outperform | Barrington Research |
| 10/14/2022 | $26.00 | Equal-Weight | Stephens |
| 3/9/2022 | Outperform → Mkt Perform | Barrington Research | |
| 3/9/2022 | Overweight → Equal-Weight | Stephens & Co. | |
| 3/9/2022 | $35.00 | Overweight → Equal-Weight | Stephens |
4 - Anika Therapeutics, Inc. (0000898437) (Issuer)
4 - Anika Therapeutics, Inc. (0000898437) (Issuer)
4 - Anika Therapeutics, Inc. (0000898437) (Issuer)
SC 13G/A - Anika Therapeutics, Inc. (0000898437) (Subject)
SC 13D/A - Anika Therapeutics, Inc. (0000898437) (Subject)
SC 13D/A - Anika Therapeutics, Inc. (0000898437) (Subject)
WEST BRIDGEWATER, Mass., Oct. 31, 2024 /PRNewswire/ -- Executive management from Primo Medical Group along with others, combined to acquire Arthrosurface, Inc., a leading provider of joint restoration and preservation solutions for active patients, from Anika Therapeutics (NASDAQ:ANIK). Two former Arthrosurface leaders joined the Primo Medical Group executives in this strategic acquisition which ensures that Arthrosurface's position as a leader in orthopedic joint preservation solutions will resume with its portfolio of innovative products and expertise. Arthrosurface: A Pione
Updating 2024 fiscal year guidance to reflect announced changes to business strategy, including the sale of Arthrosurface and planned divestiture of Parcus Medical, and U.S. OA Pain Management headwinds Strategy to focus on market leading OA Pain Management and high-growth Regenerative Solutions Company to categorize revenue into OEM Channel and Commercial Channel; Commercial Channel remains on track to achieve ~17% CAGR since 2021 with recent performance fueled by the IntegrityTM Implant System, which grew 40%+ sequentially in the third quarter with more than 500 surgeries since launch First module of Hyalofast® PMA filed in October; important hurdle addressed regarding Cingal® NDA filin
BEDFORD, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global joint preservation company focused on early intervention orthopedics, today announced the divestiture of its Arthrosurface business and the intention to divest of the Parcus Medical business. These decisions are the result of the Company's ongoing company-wide strategic review. Management Commentary "The goal of our previously announced strategic review is to drive the most optimal capital allocation structure and focus on the products that deliver the highest total return on invested capital and maximize shareholder value. Today's actions position Anika to fully focus on our profitab
Barrington Research reiterated coverage of Anika Therapeutics with a rating of Outperform and set a new price target of $25.00 from $37.00 previously
Barrington Research upgraded Anika Therapeutics from Mkt Perform to Outperform and set a new price target of $24.00
Barrington Research downgraded Anika Therapeutics from Outperform to Mkt Perform
Sends Letter to Masimo Shareholders and Releases 160-Page Investor Presentation Urges Shareholders to Help Deliver Immediate Change by Voting for Both of Politan's Independent and Ideally Qualified Nominees Darlene Solomon and William Jellison on the WHITE Card Shareholders Can Visit www.AdvanceMasimo.com for Further Information Politan Capital Management (together with its affiliates, "Politan"), an 8.9% shareholder of Masimo Corporation ("Masimo" or the "Company") (NASDAQ:MASI), today sent a letter to the Company's shareholders outlining why a majority of truly independent directors are urgently needed in the Masimo boardroom. Politan also released a detailed investor presentation m
Appoints Joseph Capper and William Jellison to Board of DirectorsAnnounces New $40 Million Share Repurchase Program BEDFORD, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global joint preservation company in early intervention orthopedics, today announced that it has entered into a cooperation agreement with Caligan Partners LP ("Caligan"). As part of the agreement, Joseph Capper, CEO of MIMEDX, and William Jellison, former CFO of Stryker, have been appointed to the Company's Board of Directors, effective immediately. Messrs. Capper and Jellison have nearly 50 years of combined experience building value and driving transformative growth at MedTech compa
BEDFORD, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global joint preservation company in early intervention orthopedics, today announced that it has appointed Steve Griffin as the Company's Executive Vice President, Chief Financial Officer ("CFO") and Treasurer, effective June 3, 2024. He succeeds Michael Levitz, who has decided to step down as CFO after almost four years with the company. Mr. Levitz will remain with the Company through December 31, 2024, to ensure a smooth transition. "We are pleased to welcome Steve to Anika as we focus on accelerating our pivot to profitability," said Cheryl Blanchard, Ph.D., Anika's President and CEO. "Steve
Updating 2024 fiscal year guidance to reflect announced changes to business strategy, including the sale of Arthrosurface and planned divestiture of Parcus Medical, and U.S. OA Pain Management headwinds Strategy to focus on market leading OA Pain Management and high-growth Regenerative Solutions Company to categorize revenue into OEM Channel and Commercial Channel; Commercial Channel remains on track to achieve ~17% CAGR since 2021 with recent performance fueled by the IntegrityTM Implant System, which grew 40%+ sequentially in the third quarter with more than 500 surgeries since launch First module of Hyalofast® PMA filed in October; important hurdle addressed regarding Cingal® NDA filin
BEDFORD, Mass., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its third quarter 2024 financial results before the opening of the market on Thursday, October 31, 2024, followed by a conference call at 8:30 a.m. ET to discuss its results and business highlights. The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (international) and providing the conference ID number 31842. A live audio webcast and accompanying presentation materials will be available in the Investor Relations section of Anika's website,
Expanded Regenerative Solutions portfolio with full market release of the Integrity™ Implant System, a hyaluronic acid (HA)-based scaffold for rotator cuff and other tendon repairs, generating significant market demand Delivered revenue in line with expectations with 15% adjusted EBITDA margins; Strong first half 2024 international OA Pain Management revenue growth of 17% Enhanced capital allocation strategy with new $40 million share repurchase program announced in May 2024; Continuing to optimize spending to support HA-based OA Pain Management and Regenerative Solutions growth BEDFORD, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a glob
Integrity and its complete arthroscopic instrumentation platform are now fully available in the U.S., expanding Anika's proprietary hyaluronic acid (HA) regenerative portfolioOver 300 surgeries completed during the limited market release, highlighting the growing interest and commercial demand across a wide range of tendon repairs
In the latest quarter, 4 analysts provided ratings for Anika Therapeutics (NASDAQ:ANIK), showcasing a mix of bullish and bearish perspectives. The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 2 2 0 0 Last 30D 0 0 1 0 0 1M Ago 0 1 0 0 0 2M Ago 0 0 0 0 0 3M Ago 0 1 1 0 0 In the assessment of 12-month price targets, analysts unveil insights for Anika Therapeutics, presenting an average target of $30.0, a high estimate of $37.00, and a low estimate of $22.00. Consistency is reflected as the current
Stephens & Co. analyst George Sellers reiterates Anika Therapeutics (NASDAQ:ANIK) with a Equal-Weight and maintains $24 price target.
10-Q - Anika Therapeutics, Inc. (0000898437) (Filer)
8-K - Anika Therapeutics, Inc. (0000898437) (Filer)
8-K - Anika Therapeutics, Inc. (0000898437) (Filer)